



## Pletal<sup>®</sup> (cilostazol) – New warning

- On May 17, 2017 the FDA approved an update to the *Warnings and Precautions* section of the [Pletal \(cilostazol\)](#) drug label regarding left ventricular outflow tract obstruction.
- Pletal is indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
- Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum.
- Patients should be monitored for the development of a new systolic murmur or cardiac symptoms after starting Pletal.
- Pletal carries a boxed warning stating that it is contraindicated in heart failure patients.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.